Tislelizumab, Another PD1 Inhibitor, Shows Promise in NSCLC

Integration of immunotherapy into the therapeutic plan for patients with metastatic non-small-cell lung cancer (NSCLC) lacking an actionable mutation is standard of care, based on significant improvements in overall survival compared to chemotherapy alone. Several immune checkpoint inhibitors have been FDA approved for use in the front-line setting, alone or in combination with platinum doublet chemotherapy.

Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, in combination with chemotherapy was evaluated in the front-line setting for metastatic squamous NSCLC. In RATIONALE 307, an open-label, multicenter phase 3 trial, 355 patients in China were randomized to one of three regimens: 1). tislelizumab (200 mg) …